摘要:
Methods, compounds, compositions and kits that relate to pretargeted delivery of diagnostic and therapeutic agents are disclosed. In particular, methods for radiometal labeling of biotin and for improved radiohalogenation of biotin, as well as related compounds, are described. Also, clearing agents, anti-ligand-targeting moiety conjugates, target cell retention enhancing moieties and additional methods are discussed.
摘要:
Methods, compounds, compositions and kits that relate to pretargeted delivery of diagnostic and therapeutic agents are disclosed. In particular, methods for radiometal labeling of biotin, as well as related compounds, are described. Articles of manufacture useful in pretargeting methods are also discussed.
摘要:
Chelating compounds of specified structure are useful for radiolabeling targeting proteins such as antibodies as well as proteinaceous and non-proteinaceous ligands and anti-ligands. The radiolabeled antibodies, ligands or anti-ligands, or catabolites thereof, demonstrate improved biodistribution properties, including reduced localization within the intestines.
摘要:
The present invention provides methods for directing the biodistribution of molecules that are not generally specifically excreted via the renal pathway to renal excretion. The methods employ conjugates or complexes containing a directed biodistribution molecule (DBM) and one or more bound molecules, wherein the biodistribution of the conjugate or complex is directed to renal excretion in vivo by the DBM component thereof.
摘要:
Chelating compounds of specified N.sub.2 S.sub.2 N.sub.3 S derived structure are useful for radiolabeling targeting molecules such as antibodies. Cleavable ester orthioester linkers connect the radionuclide metal chelates to the antibodies. The radiolabeled antibodies have improved biodistribution properties, including reduced localization within the intestines and kidneys.
摘要:
Substituted imidazole derivatives that bind to GABAA receptors are provided. Such compounds may be used to modulate ligand binding to GABAA receptors in vivo or in vitro, and are particularly useful in the treatment of a variety of central nervous system (CNS) disorders in humans, domesticated companion animals and livestock animals. Compounds provided herein may be administered alone or in combination with one or more other CNS agents to potentiate the effects of the other CNS agent(s). Pharmaceutical compositions and methods for treating such disorders are provided, as are methods for using such ligands for detecting GABAA receptors (e.g., receptor localization studies).
摘要翻译:提供了与GABA A A受体结合的取代的咪唑衍生物。 这样的化合物可用于在体内或体外调节配体与GABA A A受体的结合,并且特别可用于治疗人类中的各种中枢神经系统(CNS)紊乱,驯养伴侣动物 和牲畜。 本文提供的化合物可以单独施用或与一种或多种其它CNS剂组合施用,以增强其它CNS剂的作用。 还提供了用于治疗这种病症的药物组合物和方法,以及使用这种配体检测GABA A受体的方法(例如,受体定位研究)。
摘要:
Methods, compounds, compositions and kits that relate to pretargeted delivery of diagnostic and therapeutic agents are disclosed. In particular, methods for radiometal labeling of biotin and for improved radiohalogenation of biotin, as well as related compounds, are described. Also, clearing agents, anti-ligand-targeting moiety conjugates, target cell retention enhancing moieties and additional methods are discussed.
摘要:
Methods, compounds, compositions and kits that relate to pretargeted delivery of diagnostic and therapeutic agents are disclosed. Biotinamido-N-methylglycyl-seryl-O-succinamido-benzyl DOTA is disclosed.
摘要:
Methods, compounds, compositions and kits that relate to pretargeted delivery of diagnostic and therapeutic agents are disclosed. In particular, methods for radiometal labeling of biotin, as well as related compounds, are described. Articles of manufacture useful in pretargeting methods are also discussed.
摘要:
Protein, ligand and anti-ligand conjugated chelated metal radionuclides are provided for use in vivo. Intermediates are provided for preparing the compositions efficiently.